In the wake of a restructuring of its genomic analysis business, Roche today reported declining year-to-date sales for the unit that includes that business.
Revenues for Roche's Applied Science unit, one of five business areas of its diagnostics division, decreased five percent at constant exchange rates during the first nine months of 2012, to CHF 535 million ($577 million).
Applied Science's genomic analysis business comprises 454 sequencing and NimbleGen microarrays. Roche said in June that it would shed microarrays by the end of this year, except for products related to DNA sequence capture (IS 6/12/2012).
The genomic analysis business had an even steeper year-to-date decline – 21 percent – than Applied Science as a whole, but the company did not break out those revenues.
Roche said in a statement that Applied Science sales "continued to reflect low public research funding and increasing competition in sequencing, with additional impacts from the restructuring initiated in the second quarter."
Restructuring of Applied Science is now "largely completed" and the unit "continued to invest in sequencing and expanded its leading offering of sequence capture products," according to the company.
Earlier this month, Roche launched several new SeqCap EZ capture products, including two exome kits and two disease-specific panels (IS 10/2/2012). The firm also released two gene sequencing primer sets for leukemia research on its 454 GS FLX and GS Junior systems this spring (CSN 4/25/2012).
Roche did not specify how it will invest in sequencing, but earlier this year, after its bid to acquire Illumina failed, the firm said it would put funding into "disruptive technologies" and continue existing sequencing development partnerships with IBM, DNA Electronics, and several academic collaborators.